A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Otsuka Pharmaceutical.

Editor’s Note: This article was updated on a continuous basis for news announced from Wednesday April 25, 2018 date to Tuesday May 1, 2018.

FDA OKs Otsuka’s Kidney Disease Drug Jynarque
The US Food and Drug Administration (FDA) has approved Otsuka Pharmaceutical’s Jynarque (tolvaptan) as a drug treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

The medication has been approved as a treatment for adults with ADPKD in Japan, the European Union, Canada, South Korea, Switzerland, Hong Kong, Australia, Turkey and Taiwan.

Source: Otsuka Pharmaceutical